LeMaitre Vascular (NASDAQ:LMAT) Given New $118.00 Price Target at Citizens Jmp

LeMaitre Vascular (NASDAQ:LMAT) had its price objective boosted by Citizens Jmp from $113.00 to $118.00 in a research note published on Thursday morning,Benzinga reports. The brokerage currently has a market outperform rating on the medical instruments supplier’s stock.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Cantor Fitzgerald restated a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research note on Monday, November 10th. Roth Mkm reaffirmed a “buy” rating and set a $108.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Barrington Research restated an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Friday, February 20th. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $106.50.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $113.69 on Thursday. The stock’s 50-day simple moving average is $86.55 and its 200-day simple moving average is $88.30. The firm has a market capitalization of $2.58 billion, a PE ratio of 45.29, a price-to-earnings-growth ratio of 2.03 and a beta of 0.72. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $115.33. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. The company had revenue of $64.45 million for the quarter, compared to analyst estimates of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 15.02%. The firm’s revenue was up 15.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, equities research analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be issued a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio is 31.87%.

Hedge Funds Weigh In On LeMaitre Vascular

A number of large investors have recently bought and sold shares of LMAT. Mercer Global Advisors Inc. ADV increased its stake in shares of LeMaitre Vascular by 11.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 3,606 shares of the medical instruments supplier’s stock worth $292,000 after acquiring an additional 371 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 139 shares during the period. Empowered Funds LLC acquired a new stake in shares of LeMaitre Vascular in the 4th quarter valued at approximately $289,000. nVerses Capital LLC purchased a new stake in shares of LeMaitre Vascular in the fourth quarter valued at approximately $234,000. Finally, Voloridge Investment Management LLC raised its position in LeMaitre Vascular by 70.0% in the fourth quarter. Voloridge Investment Management LLC now owns 62,909 shares of the medical instruments supplier’s stock worth $5,102,000 after acquiring an additional 25,901 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

More LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat and revenue growth — LMAT reported $0.68 EPS vs. $0.67 expected and revenue of $64.45M (vs. $62.98M est.), with revenue up 15.7% year-over-year; this is a primary catalyst for the stock move. Earnings Press Release
• Positive Sentiment: Raised guidance — Management boosted Q1 2026 EPS guidance to $0.640–$0.690 (vs. $0.62 consensus) and FY2026 EPS to $2.810–$3.010 (vs. $2.61 consensus), giving investors clearer upside to future earnings. Guidance Details
• Positive Sentiment: Dividend increase — LMAT declared a quarterly dividend of $0.25 (25% increase from $0.20), raising the yield to ~1.1% and signaling confidence in cash flow; ex-dividend March 12. (Company announcement)
• Positive Sentiment: Analyst bullishness — Roth MKM reaffirmed a “buy” and raised its price target to $117 (from $108), and Citizens JMP raised its target to $118 with a “market outperform” rating; both moves support upside expectations. Benzinga TickerReport
• Neutral Sentiment: Barrington Research raised its price target to $105 and kept an “outperform” rating — a positive signal on the rating but the target is below the current market price, making the impact mixed. Benzinga
• Neutral Sentiment: Relevant reads/transcript — The Q4 2025 earnings call transcript and analyst write-ups are available for investors who want detail on revenue drivers and margin outlook. Earnings Call Transcript
• Negative Sentiment: Wells Fargo raised its target to $94 but maintains an “equal weight” rating — the target sits materially below the current price, which could cap upside or encourage some selling from risk-averse holders. Benzinga

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.